Determining a biological tissue structural marker for diagnosis of a disease
The present disclosure relates to determining a biological tissue structural marker for diagnosis of a disease using a biological tissue characterization technique. A method for determining a structural marker for a diagnosis of a disease can include measuring a first molecular structure of a biological tissue of a first population of animals, after a carcinogenic or pathogenic substance was introduced into the first population. A second molecular structure of the biological tissue of a second population of animals can be measured, wherein the second population did not receive the carcinogenic or pathogenic substance. A first and a second structural marker of the molecular structures of the biological tissue of the first and second populations, respectively, can be identified and compared to determine that the first structural marker is indicative that the biological tissue of the first population of animals was affected by the disease.
1 . A method for determining a structural marker for a diagnosis of a disease, the method comprising:
introducing a carcinogenic or pathogenic substance into a first population of animals, wherein the carcinogenic or pathogenic substance is intended to cause the first population of animals to contract a disease that affects a molecular structure of a biological tissue of the first population of animals;
measuring a first molecular structure of the biological tissue of the first population of animals, after the carcinogenic or pathogenic substance was introduced into the first population of animals, using a biological tissue characterization technique;
measuring a second molecular structure of the biological tissue of a second population of animals using the biological tissue characterization technique, wherein the second population of animals did not receive the carcinogenic or pathogenic substance;
identifying a first structural marker of the first molecular structure of the biological tissue of the first population of animals;
identifying a second structural marker of the second molecular structure of the biological tissue of the second population of animals;
comparing the first structural marker with the second structural marker; and
determining that the first structural marker is indicative that the biological tissue of the first population of animals was affected by the disease.
2 . The method of claim 1 , wherein the biological tissue is one or more of collagens that diffract x-ray light, keratins that diffract x-ray light, lipids that diffract x-ray light, actin that diffracts x-ray light, myosin that diffracts x-ray light, and glycoproteins that diffract x-ray light.
3 . The method of claim 1 , wherein the biological tissue characterization technique comprises non-invasive observation of the molecular structure of the biological tissue of the first population of animals in vivo.
4 . The method of claim 3 , wherein the biological tissue comprises one or more of nails, hairs, wool, horns, and claws.
5 . The method of claim 1 , wherein the biological tissue characterization technique comprises in vitro observation of the molecular structure of a sample of the biological tissue of the first population of animals.
6 . The method of claim 5 , wherein the biological tissue comprises one or more of nails, hair, wool, horns, claws, breast tissue, brain tissue, skin, muscle tissue, fat, and ear tissue.
7 . The method of claim 1 , wherein the biological tissue characterization technique comprises one or more of: X-ray diffraction, luminescent spectroscopy, selective laser spectroscopy, Raman spectroscopy, spectroscopy in the visible spectral region, and infrared spectroscopy.
8 . The method of claim 7 , further comprising:
controlling one or more characterization devices performing the biological tissue characterization technique using a computer workstation;
performing digital image processing of one or more images related to the molecular structure of the biological tissue using the computer workstation; and
storing and displaying data received from the one or more characterization devices performing the one or more characterization techniques.
9 . The method of claim 8 , wherein the digital image processing comprises one or more of: producing a discrete two-dimensional Fourier transform of the one or more images, performing image segmentation of the one or more images, defining descriptors of boundaries or regions in the one or more images, and recognizing objects in the one or more images.
10 . The method of claim 7 , wherein the X-ray diffraction uses an X-ray tissue diffractometer comprising:
a positioning area for the biological tissue;
an X-ray beam delivery system providing a primary incident micro-beam of X-rays directed at the biological tissue to be analyzed, wherein the X-ray beam delivery system comprises:
a radiation source operating in a continuous mode;
an apparatus forming the primary incident micro-beam of X-rays;
a monochromator; and
at least one of a collimating optical device and a focusing optical device; and
a receiver comprising a two-dimensional pixel detector designed to detect a transmitted micro-beam of X-rays passed through the biological tissue as well as part or all of X-rays that are diffracted by the biological tissue.
11 . The method of claim 10 , wherein the two-dimensional pixel detector is inside a protection container, wherein the protection container comprises a vacuum or an inert gas environment, and a window or wall facing the biological tissue that is substantially transparent to the X-rays.
12 . The method of claim 11 , wherein the inert gas environment comprises neon or helium.
13 . The method of claim 10 , wherein the X-ray tissue diffractometer further comprises a chamber filled with an inert gas wherein the chamber is located between the two-dimensional pixel detector and the tissue during an X-ray diffraction characterization of the molecular structure of the biological tissue.
14 . The method of claim 13 , wherein the inert gas environment comprises neon or helium.
15 . The method of claim 1 , wherein the disease comprises a disease of the immune system, a disease of the skin, a rheumatic disease, a urological disease, an endocrine disease, a disease of the veins, a disease of the lymph nodes, a disease of an endocrine organ, a disease of a mammary gland, a disease of a respiratory organ, a disease of a digestive organ, a disease of the heart, a disease of the blood vessels, a disease of the colon, a disease of the ear, a disease of the throat, a disease of the nose, or cancer.
16 . The method of claim 15 , wherein the cancer comprises cancer of the stomach, liver, rectum, colon, esophagus, pancreas, bladder, vagina, lung, oropharynx, nasopharynx, oral mucosa, tongue, skin, brain, thyroid, prostate, breast, cervix, and/or ovary.
17 . The method of claim 1 , wherein the first and second population of animals comprises one or more of: rabbits, guinea pigs, rats, white rats, gray rats, mice, white mice, gray mice, golden hamsters, and monkeys.
18 . The method of claim 1 , wherein the carcinogenic or pathogenic substance comprises one or more of: acetaldehyde, 4-aminobiphenyl, aristolochic acid, plants containing aristolochic acid, asbestos, arsenic, arsenic compounds, azathioprine, benzene, benzidine, benzopyrene, beryllium, beryllium compounds, chlornaphazine, nitrogenous mustard gas, chloromethyl ether, methyl ether, 1,3-butadiene, 1,4-butanediol, cadmium, cadmium compounds, chlorambucil, methyl-CCNU, chromium (VI) compounds, cyclosporine, cyclophosphamide, diethylstilboestrone, Epstein-Barr virus, nonsteroidal estrogens, steroid estrogens, erionite, ethylene oxide, etoposide, combination of etoposide with cisplatin and bleomycin, formaldehyde, bacterium, Helicobacter Pylori Hepatitis B virus, hepatitis C virus, melphalan, metoxalen in combination with ultraviolet A-radiation, 4,4′-methylene-bis-(o-chloraniline) (MOCA), mustard gas, 2-naphthylamine, neutron radiation, tobacco nitrosamine, 4-(N-methylnitrosamine)-1-(3-pyridyl)-1-butanone, N-nitrosonornicotine, opisthorchiasis, plutonium-239 and its decay products, and plutonium-240 and other isotopes.
19 . The method of claim 1 , further comprising:
measuring a series of molecular structures of the biological tissue of the first population of animals at a plurality of times using the biological tissue characterization technique; and
comparing a series of structural markers of the series of molecular structures of the biological tissue of the first population of animals with the second structural marker of the second molecular structure of the biological tissue of the second population of animals.
20 . The method of claim 19 , wherein the comparing the series of structural markers of the series of molecular structures of the biological tissue of the first population of animals with the second structural marker of the second molecular structure of the biological tissue of the second population of animals further comprises:
determining a regression coefficient of a function fit to data from the measurements of the series of molecular structures of the biological tissue of the first population of animals.
21 . The method of claim 19 , further comprising identifying a stage of the disease at one or more of the plurality of times.
22 . The method according to claim 1 , wherein the first structural marker comprises one or more of: a defect in the molecular structure of the biological tissue, a periodicity of fibrils in the biological tissue, a periodicity of collagen fibrils in the biological tissue, a periodicity of keratin fibrils in the biological tissue, and a feature of the first molecular structure that is different from a corresponding feature of the second molecular structure.